Latest news with #BioNeMo
Yahoo
16-06-2025
- Business
- Yahoo
Nvidia (NVDA) Teams With Novo Nordisk to Advance AI Drug Discovery
Nvidia (NVDA, Financials) said Tuesday it is partnering with Novo Nordisk to accelerate drug discovery using its generative and agentic AI tools. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The collaboration will use Denmark's sovereign AI supercomputer, Gefion, operated by DCAI and powered by Nvidia's DGX SuperPOD. Novo Nordisk will deploy Nvidia's BioNeMo, NeMo and NIM platforms to support early research, clinical development and biomedical modeling. Nvidia said the work aims to build custom AI models that help scientists identify cellular responses and develop drug-like molecules more efficiently. Novo Nordisk said the infrastructure will enable experiments at unprecedented scale. Gefion is also being used by Danish startups and health agencies to build AI care systems and unify national health data, Nvidia said. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
11-06-2025
- Business
- Forbes
Nvidia Announces Massive New Initiatives in Pharma And Clinical Research
Nvidia has quickly become a leader in the AI ecosystem. Founder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris keynote that the company has inked two new large partnerships to advance the company's work in healthcare and life-sciences. The first is with European based global pharmaceutical giant, Novo Nordisk, to advance drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation's (DCAI) Gefion AI supercomputer. Novo Nordisk will utilize Gefion and a variety of Nvidia platforms such as BioNeMo, Nim, and Omniverse to build and develop customized AI models, foster agentic AI workflows and even create simulation and digital twin environments to advance physical AI applications. The primary goal will be to use these tools to better understand potential drug candidates and structures in order to build molecular models that can further the drug discovery and development pipeline. Rory Kelleher, senior director of business development for life sciences at Nvidia, explains that drug discovery can claim massive benefits from generative AI, especially in the R&D space. Mishal Patel, senior vice president of AI and digital innovation at Novo Nordisk, comments that the combination of Gefion and Nvidia's computing platforms is an unprecedented approach and will enable the building of custom models that can truly empower better efficiency and efficacy. More generally, Gefion is a computational behemoth and has been used by numerous enterprises to advance their computing capabilities; for example, Danish startup Teton has been working with Nvidia and Gefion to build out an AI care companion for clinical settings. The second partnership that Nvidia announced today is with IQVIA to advance the use of AI agents in the clinical research and commercialization spaces. The companies will collaborate to launch multiple AI powered agents to accelerate pharmaceutical development workflows for biotech and medical device customers globally. Importantly, the new agents will be 'orchestrator agents,' meaning that they will act as supervisors for groups of 'sub-agents' that each have their own specialties; the supervising agent will route a received task to the appropriate sub-agent, enabling an efficient and automated workflow. Using this technology, IQVIA is hoping to tackle some of the hardest problems in the drug development and pharmaceutical workflows. For example, clinical trials often require a significant amount of work to launch and execute. Agents can help identify targets, develop a knowledge base using existing research databases and even review clinical data to better understand insights and automate the review process. Avinob Roy, vice president and general manager at IQVIA, explains that AI agents will transform the entire 'molecule to market' lifecycle. Overall, the news comes at a time when Nvidia's reach into the AI ecosystem has been incredibly impactful. The company indicated in its latest quarterly report a continuing surge in demand for its GPUs and hardware ecosystem. Though most traditionally a hardware giant, it has also increasingly diversified its work into the cloud and software ecosystems, furthering its moat in the AI space. Undoubtedly, there is stiff competition in the AI race. With regard to hardware alone, technology giants such as Google and Amazon depend heavily on Nvidia for its GPUs; however, the companies are also rapidly developing their own silicon products, such as Google's work with tensor processing units (TPUs) and Amazon's customized silicon products (i.e., Trainium, Graviton and Inferentia). With regard to healthcare and life-sciences more broadly, all of the large technology hyperscalers are investing billions of dollars in these fields. For example, one of the most prominent success stories is Alphabet's Isomorphic Labs and its work with drug development models. Companies like Microsoft are also rolling out new enterprise grade tools and infrastructure capabilities to empower traditional life-science companies. Indeed, the innovation is rapid and unprecedented. Despite the perception of a 'competition' however, there is no need for a clear cut winner. The reality of this progress across the entire spectrum of technology companies is that ultimately, both the healthcare and life-sciences industries stand to gain immense benefits.
Yahoo
19-03-2025
- Science
- Yahoo
Sapio Sciences Makes AI-Native Drug Discovery Seamless with NVIDIA BioNeMo
Integration of the NVIDIA BioNeMo platform enhances AI capabilities across the drug discovery lifecycle BALTIMORE, March 19, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into Sapio ELN (Electronic Lab Notebook), helping to streamline workflows and improve decision-making in drug discovery. With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specific AI frameworks, pre-trained models, and generative AI tools to streamline the identification of potential drug candidates and improve target selection accuracy. NVIDIA BioNeMo provides scientists with a framework for training and deploying large biomolecular language models at supercomputing scale. The integration of BioNeMo into the Sapio Platform provides scientists with embedded in silico tools, enabling them to, for example, generate novel candidate molecules early in the research process and test their docking with a target protein. With AI-driven molecular simulations available within a single, unified workflow, researchers can streamline their processes, enhance innovation, and accelerate the transition from discovery to development. Within Sapio ELN, researchers can access BioNeMo NIM microservices to rapidly identify and optimize drug candidates using AI-driven molecular modeling, including AlphaFold2 NIM for predicting accurate 3D protein structures; MoIMIM NIM to enable the design and optimization of small molecules; and DiffDock NIM, an AI-powered docking model developed by MIT. These models provide scientists with easy access to AI-driven tools without extensive setup, ensuring faster, more efficient research workflows. Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, commented: "AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA's powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyze, and visualize both chemical and biological results." Kevin continued: "We are working with NVIDIA to equip scientists and researchers with the most advanced AI tools to drive innovation in life sciences. This collaboration is a major step toward making AI an integral part of the drug discovery process, helping researchers make faster, data-driven decisions and improve research outcomes." Anthony Costa, Director, Digital Biology at NVIDIA, commented: "Integrating BioNeMo into Sapio's AI-driven research platform gives scientists access to advanced generative AI models for drug discovery. With AlphaFold2, MoIMIM, and DiffDock NIMs, researchers can predict, optimize, and validate drug candidates with greater speed and accuracy. This work underscores AI's growing role in transforming pharmaceutical research and accelerating the path to breakthrough treatments." Integrating NVIDIA technologies into the Sapio Platform is one of the many ways Sapio Sciences is helping to improve and accelerate biopharma discovery, clinical diagnostics, and drug manufacturing. Find out more about the Sapio/NVIDIA integration here. About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts Media contacts: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@
Yahoo
18-03-2025
- Business
- Yahoo
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
The medical device industry is undergoing a profound change in 2025, driven by advancements in generative AI and agentic AI. At the forefront of this revolution are players like NVIDIA NVDA, whose AI computing platforms are accelerating AI-powered medical applications and capturing investors' attention. NVIDIA's Clara platform, powered by generative AI, is enabling real-time medical imaging enhancements and predictive diagnostics. Additionally, NVIDIA's BioNeMo, a generative AI model tailored for life sciences, is advancing drug discovery and biomarker identification, directly impacting the development of AI-integrated medical devices. In January, NVIDIA joined industry leaders across genomic research, drug discovery, clinical trials and patient care to discuss how predictive, generative and agentic AI are driving advancements in healthcare. Here we discuss three MedTech leaders, Resmed RMD, GE HealthCare GEHC and Medtronic MDT, which are embedding different forms of AI into their devices, allowing systems to autonomously analyze patient data, adjust treatment protocols and improve decision-making without constant human intervention. For instance, AI-driven insulin pumps and robotic surgical systems are becoming more adaptive, offering unprecedented precision in treatment. WHO currently estimates a projected shortfall of 11 million health workers by 2030. With the healthcare sector facing one of the most severe labor shortages, AI's role in optimizing workflows and improving patient care has become increasingly crucial. Regulatory bodies are fast evolving to accommodate AI-enabled devices, and the FDA and European MDR are working on new frameworks for approving autonomous systems in healthcare. The introduction of predetermined change control plans (PCCP) and other frameworks allows AI models to evolve post-market while maintaining compliance, thus accelerating industry-wide adoption. As a result, AI-powered medical devices are reaching the market faster while maintaining stringent safety standards. Apart from deals with NVDA, MedTech giants are also seen collaborating with AI leaders like Google Health and Microsoft to co-develop cutting-edge solutions. These alliances fast-track AI integration across imaging, diagnostics and device automation. Resmed: It is actively progressing in the field of utilizing digital health technology to convert big data into valuable information. The company has captured a significant foothold in the digital health market with approximately 21 billion nights of medical data in the cloud and 27 million 100% cloud-connectable medical devices sold in more than 140 countries worldwide. ResMed aims to improve 500 million lives through better residential healthcare by 2030. The company has been expanding AI products in AirView. It continues to expand its portfolio of AI-driven capabilities, as well as customer-facing AI products that will be launched into the market from its ecosystem. This $34.8 billion market cap stock has a Zacks Rank #2 (Buy) and a long-term expected earnings growth rate of 16%. In 2025, Resmed is expected to record an earnings growth rate of 22.7%. Over the past 60 days, the Zacks Consensus Estimate for RMD's 2025 earnings has moved up by 13 cents. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ResMed Inc. price | ResMed Inc. Quote GE HealthCare: The company is actively using artificial intelligence and machine learning to provide clinical decision support and highly personalized therapies enabled by more precise diagnostics and remote patient monitoring. In the United States, hospitals and outpatient centers are accelerating purchases of advanced imaging systems, ultrasound devices and interventional solutions, supported by a need to upgrade aging infrastructure and enhance operational efficiency. The shift toward outpatient procedures, particularly in orthopedics, cardiology and surgical imaging, is fueling demand for C-arms, ultrasound and PET scanners. This $39.03 billion market cap stock has a Zacks Rank #3 (Hold) and a long-term expected earnings growth rate of 6.2%. In 2025, GE Healthcare is expected to record earnings growth of 4.7%. Over the past 30 days, the Zacks Consensus Estimate for GAHC's 2025 earnings has moved up by 4 cents. GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote Medtronic: It is also actively integrating AI across its portfolio to enhance clinical outcomes. The company's GI Genius system utilizes AI to assist physicians in detecting colorectal polyps during colonoscopies. Further, the Touch Surgery Enterprise platform is an AI-powered surgical video management and analytics system. This apart, Medtronic has developed adaptive deep brain stimulation systems that use AI to tailor electrical stimulation based on real-time neural activity. MDT, with a market capitalization of $119.6 billion, currently carries a Zacks Rank #3. It has a long-term expected earnings growth rate of 7.3%. In fiscal 2025, MDT is expected to record earnings growth of 5%. Over the past 30 days, the Zacks Consensus Estimate for Medtronic's fiscal 2025 earnings has moved up by a penny. Medtronic PLC price | Medtronic PLC Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report ResMed Inc. (RMD) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
1724913086-0%2FBeFunky-collage%5D_______-(15)1724913086-0.jpg&w=3840&q=100)
Express Tribune
20-02-2025
- Science
- Express Tribune
Nvidia unveils powerful AI system for genetic research
A smartphone with a displayed NVIDIA logo is placed on a computer motherboard in this illustration taken March 6, 2023. PHOTO:REUTERS AI chipmaker Nvidia and research partners have created what they call the largest artificial intelligence system yet for biological research, the company said on Wednesday, aiming to speed up breakthroughs in medicine and genetics. The new AI system, called Evo 2, can read and design genetic code across all forms of life. Scientists have high hopes that such AI technology will dramatically accelerate research by spotting patterns in vast amounts of data that would normally take years to analyze by hand. The system learned from nearly 9 trillion pieces of genetic information taken from over 128,000 different organisms, including bacteria, plants, and humans. In early tests, it accurately identified 90 percent of potentially harmful mutations in BRCA1, a gene linked to breast cancer. Scientists say this could help develop more precise treatments, including gene therapies that only target specific cells. The model was built using 2,000 Nvidia H100 processors on Amazon's cloud infrastructure. Developed with the Arc Instiftute and Stanford University, Evo 2 is now freely available to scientists worldwide through Nvidia's BioNeMo research platform. "Designing new biology has traditionally been a laborious, unpredictable and artisanal process," said Brian Hie, assistant professor at Stanford University. AFP
